VKTX - Viking Therapeutics, Inc.
| Previous Close | 8.59 |
| Open | 8.65 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 800 |
| Day's Range | 8.35 - 8.89 |
| 52 Week Range | 3.69 - 24.00 |
| Volume | 2,613,104 |
| Avg. Volume | 3,554,114 |
| Market Cap | 635.284M |
| Beta (3Y Monthly) | 3.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.00 |
- Market Realist•7 days ago
VKTX or ENTA: What to Expect from Revenue Growth in 2019
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
- Market Realist•7 days ago
What Are Analysts Recommending for VKTX and ENTA?
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
- Zacks Small Cap Research•10 days ago
VKTX: VK2809 5 mg Data Presented at EASL…
In addition, all nine patients in the 5 mg cohort experienced ≥ 30% reduction in liver fat and 77.8% were ‘super-responders’, defined as experiencing ≥ 50% reduction in liver fat. For those who may argue that the two patient populations are too dissimilar to offer a valid comparison, we believe that the very similar placebo responses seen in both outcomes in the table below indicate that the two populations are in fact quite similar.
Bloomberg•11 days agoViking Therapeutics Jumps as New Liver Drug Gets Positive Results
Seven of nine patients getting Viking’s VK2809 at a dose of 5 milligrams once a day saw their liver fat cut by 50 percent or more. The biggest reduction in liver fat at the 5 milligram dose was 78 percent, according to data presented at the European Association for the Study of the Liver congress in Vienna. The company is also testing a 10 milligram dose.
- PR Newswire•11 days ago
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8% 88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver ...
- Motley Fool•13 days ago
Why Viking Therapeutics Stock Perked Up in March
Viking's shares received a boost from a pair of catalysts last month.
- Motley Fool•16 days ago
Here's Why Investors Are Betting Against These 2 Biotech Stocks
Are intrepid short-sellers taking advantage of misguided enthusiasm?
- PR Newswire•18 days ago
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm SAN DIEGO , April 4, 2019 /PRNewswire/ -- Viking ...
- Motley Fool•22 days ago
3 Top Value Stocks to Buy Right Now
Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.
- TheStreet.com•24 days ago
The Best Approach to Trading Lyft
Every day this week the indices have opened on an upbeat note and then sold off. If you are interested in trading it the best approach is to wait at least 30 minutes to an hour after it opens and watch for a trading range to develop. The trading range provides a mechanism for risk control and nothing more.
- PR Newswire•25 days ago
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , March 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Market Realist•25 days ago
Analysts Are Mostly Positive on Viking Therapeutics in March
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 200.82% for Viking Therapeutics (VKTX) based on the company’s closing
- MarketWatch•last month
Harry Boxer: 3 biotech stocks with momentum
Biotech stocks dominate our list of top charts to watch today. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. Invitae Corp. (NVTA) rose 71 cents to $25.75 on 1.2 million shares Thursday.
- Thomson Reuters StreetEvents•last month
Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
Q4 2018 Viking Therapeutics Inc Earnings Call
- Zacks Small Cap Research•last month
VKTX: Phase 2b Trial for VK2809 to Initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. 1) VK2809, which is an oral, liver selective agonist of the thyroid hormone receptor beta (TRβ) and is being developed for the treatment of nonalcoholic steatohepatitis (NASH). • We anticipate the company conducting a pre-IND meeting with the FDA in mid-summer 2019 and a Phase 2b study in NASH patients to be initiated in the second half of 2019.
Motley Fool•last monthViking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript
VKTX earnings call for the period ending December 31, 2018.
- PR Newswire•last month
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily - Initiation of Phase ...
- Simply Wall St.•last month
Shareholders Are Raving About How The Viking Therapeutics (NASDAQ:VKTX) Share Price Increased 346%
Viking Therapeutics, Inc. (NASDAQ:VKTX) shareholders might be concerned after seeing the share price drop 14% in the last quarter. But that doesn't change the fact that the returns over theRead More...
- Motley Fool•last month
3 Stocks That Could Double Your Money
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
- PR Newswire•2 months ago
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
Conference Call Scheduled for Wednesday, March 13 at 4:30 p.m. Eastern Time SAN DIEGO , March 6, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Motley Fool•2 months ago
Is Viking Therapeutics a Buy?
Once sky-high stocks of pharmaceutical companies pursing treatments for NASH have gotten a lot cheaper, especially this one.
- PR Newswire•2 months ago
Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
SAN DIEGO , Feb. 26, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- GlobeNewswire•2 months ago
Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
Healthcare Companies Investors are Watching
HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...
- ACCESSWIRE•2 months ago
4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.
